PMV Pharmaceuticals (PMVP) AI Stock Analysis

• Market Cap: $54.81M
• Dividend Yield: N/A
• Average Volume (3M): 238.09K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.62
• Revenue Growth: N/A
• EPS Growth: -58.47%
• Country: US
• Employees: 47
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.40
• Shares Outstanding: 53,211,506
• 10 Day Avg. Volume: 356,756
• 30 Day Avg. Volume: 238,093
• PEG Ratio: 0.06
• Price to Book (P/B): 0.44
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.50
• Enterprise Value/Market Cap: 0.34
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -294.84
• Enterprise Value/Ebitda: -0.21
• 1Y Price Target: $5.00
• Price Target Upside: 385.44% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: $1.00 ▼(-2.91% Downside)

The score is held down primarily by weak financial performance (no revenue, widening losses, and sustained cash burn), with only the low-debt balance sheet providing partial support. Technicals also lean negative with the stock below key moving averages and a negative MACD. Valuation is difficult to assess given negative earnings and no dividend yield.

Positive Factors

Low leverage / conservative debt profile

Very low reported debt gives PMV Pharmaceuticals financial flexibility over the medium term, reducing interest and refinancing pressure. For a cash-burning clinical biotech, low leverage limits insolvency risk and preserves optionality to structure future financings or partner deals without heavy fixed obligations.

Focused precision oncology franchise

A targeted focus on genetically defined cancer drivers, especially TP53-modulating small molecules, supports a differentiated scientific position. Precision targeting enables clearer patient selection, potentially higher clinical readthrough rates, streamlined development, and stronger partner interest for co-development or licensing.

Partnership-driven funding model

PMV's historical reliance on collaborations and milestone-based payments is a durable early-stage biotech model that shares development risk and reduces the need to build commercial infrastructure. Strategic partnerships can provide non-dilutive cash, validation, and access to commercialization capabilities if programs progress.

Negative Factors

Zero product revenue and widening losses

Sustained absence of product revenue with materially widening operating losses signals continued dependence on financing and unproven commercial economics. Over months, this undermines self-funding capacity, increases shareholder dilution risk, and leaves future program advancement contingent on external capital or partner deals.

Persistent and increasing cash burn

Rising negative operating and free cash flows indicate accelerating funding needs absent revenue. This structural cash burn pressures runway and strategic flexibility, likely necessitating dilutive equity raises or accelerated partnerships, which can constrain long-term plan execution and investor returns.

Eroding shareholder equity and negative ROE

Significant depletion of equity and deeply negative ROE reflect sustained value erosion from recurring losses and capital consumption. Over the medium term this reduces balance-sheet buffers, magnifies sensitivity to financing conditions, and signals the company has yet to translate R&D investment into value-accretive outcomes.

PMV Pharmaceuticals Business Overview & Revenue Model

Company Description

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.

How the Company Makes Money

PMV Pharmaceuticals generates revenue primarily through the development and commercialization of its proprietary drug candidates. The company focuses on advancing its pipeline of small-molecule therapies through clinical trials and aims to monetize these assets via out-licensing agreements, partnerships with larger pharmaceutical companies, or direct sales upon regulatory approval. Key revenue streams include milestone payments, royalties, and upfront fees from partnerships and collaborations, which are essential to funding ongoing research and development efforts. The company's financial success is closely tied to the successful advancement of its drug candidates through clinical trials and obtaining necessary regulatory approvals.

PMV Pharmaceuticals Financial Statement Overview

Summary

Overall fundamentals are weak: the company reports $0 revenue, losses are large and worsening (EBIT down to -$92.1M TTM; net loss -$82.7M TTM), and operating/free cash flow remain deeply negative (about -$73M TTM). The main offset is a low-debt balance sheet (~$0.9M total debt), but equity has fallen sharply ($359.1M in 2020 to $121.0M TTM), signaling ongoing capital erosion.

Income Statement

The income statement is weak: the company reports $0 revenue across all periods (including TTM (Trailing-Twelve-Months)), while operating losses are large and widening versus earlier years (EBIT from -$34.9M in 2020 to -$92.1M in TTM (Trailing-Twelve-Months)). Net losses remain significant (-$82.7M in TTM (Trailing-Twelve-Months)), indicating a business still in heavy investment mode with no commercial scaling visible in the provided data. A modest positive is that losses are being managed without revenue reliance typical of development-stage biotech, but overall profitability trajectory is unfavorable.

Balance Sheet

The balance sheet is a relative strength due to very low leverage: total debt is only ~$0.9M in TTM (Trailing-Twelve-Months) and debt-to-equity remains minimal (~0.7%). However, equity has declined meaningfully over time ($359.1M in 2020 to $121.0M in TTM (Trailing-Twelve-Months)), reflecting sustained losses and/or capital use. Returns on equity are deeply negative (about -48% in TTM (Trailing-Twelve-Months)), highlighting ongoing value erosion despite the conservative debt profile.

Cash Flow

Cash flow is pressured by consistent cash burn: operating cash flow is negative in every period and deteriorated to -$73.0M in TTM (Trailing-Twelve-Months) versus -$51.3M in 2024. Free cash flow is similarly negative (-$73.1M TTM (Trailing-Twelve-Months)). While free cash flow roughly tracks net loss (cash burn broadly in line with reported losses), the overall trend points to increasing funding needs unless spending is reduced or revenue sources emerge.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-64.00K	-1.14M	-1.26M	-650.00K	-1.28M	-318.00K
EBITDA	-88.86M	-73.67M	-67.70M	-72.68M	-56.54M	-34.12M
Net Income	-82.70M	-58.71M	-68.96M	-73.32M	-57.85M	-34.44M
Balance Sheet
Total Assets	133.84M	191.29M	252.15M	270.31M	331.57M	365.53M
Cash, Cash Equivalents and Short-Term Investments	129.25M	169.45M	203.06M	241.05M	297.16M	361.42M
Total Debt	931.00K	1.19M	13.29M	13.98M	11.19M	0.00
Total Liabilities	12.85M	15.21M	26.46M	24.28M	23.01M	6.41M
Stockholders Equity	121.00M	176.08M	225.69M	246.03M	308.56M	359.12M
Cash Flow
Free Cash Flow	-73.12M	-51.94M	-56.62M	-71.74M	-47.92M	-32.89M
Operating Cash Flow	-73.05M	-51.28M	-55.66M	-63.76M	-46.57M	-32.74M
Investing Cash Flow	59.47M	53.35M	-50.55M	-1.37M	-143.58M	27.91M
Financing Cash Flow	285.00K	313.00K	35.58M	958.00K	2.02M	292.97M

PMV Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.03
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PMVP, the sentiment is Negative. The current price of 1.03 is below the 20-day moving average (MA) of 1.14, below the 50-day MA of 1.20, and below the 200-day MA of 1.24, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 34.71 is Neutral, neither overbought nor oversold. The STOCH value of 6.84 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PMVP.

PMV Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
XFOR	52 Neutral	$336.63M	-0.37	-156.87%	―	2925.73%	-294.29%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PRLD	51 Neutral	$130.22M	-1.25	-103.99%	―	250.00%	15.15%
PMVP	46 Neutral	$54.81M	-0.64	-51.87%	―	―	-58.47%
GANX	46 Neutral	$67.69M	-2.53	-261.72%	―	―	42.29%
ABVC	44 Neutral	$46.17M	-7.17	-40.32%	―	56.52%	75.22%